-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 10, Fosun Pharma issued two consecutive external investment and related-party transaction announcements.
The related-party transactions were Windgothenburg and Fosun High-Tech.
The transferee shares accounted for 45% and 87%, respectively
.
Among them, Fosun Industrial, a subsidiary of Fosun Pharma, signed an "Equity Transfer Agreement" with Windgothenburg, a related party, and Fosun Industrial intends to invest US$28.
7 million in cash to acquire the 45% equity of FMH held by Windgothenburg
.
The main asset of FMH is its 100% equity interest in Breas
.
Fosun Pharma stated that this transaction does not constitute a major asset reorganization as required by the "Administrative Measures for the Major Asset Reorganization of Listed Companies"
.
Since Windgothenburg, the transferor of this transaction, is the holding subsidiary of Fosun International, the indirect controlling shareholder of the company, according to the Shanghai Stock Exchange’s Listing Rules and the “Guidelines for the Implementation of Related Party Transactions”, Windgothenburg constitutes a related party of the company and the transaction constitutes Related transactions of the company
.
It is understood that Breas and its holding subsidiaries are mainly engaged in professional ventilator design, research and development, manufacturing and sales.
Its medical and household ventilator products are sold in more than 40 countries around the world through its own channels and professional distribution networks.
Products include Vivo, Z series and other multifunctional ventilator and sleep ventilator products
.
According to the announcement, the consideration for the transaction is based on the value of all FMH shareholders’ equity as of September 30, as of September 30, which is based on the "Asset Appraisal Report" issued by Xiamen University Asset Appraisal Land and Real Estate Appraisal Co.
, Ltd.
It is determined after negotiation between the two parties in this transaction
.
After the completion of the transaction, Fosun Pharma will hold 100% of FMH
.
On the same day, Fosun Pharmaceutical Industries, a subsidiary of Fosun Pharmaceuticals, and Fosun High-Tech signed the "Equity Transfer Agreement.
" Equity
.
After the completion of the transaction, Fosun Pharmaceutical Industry will hold 87% of Xingchuang Health Technology, and Xingchuang Health Technology will be included in the scope of the consolidated financial statements of the Group
.
According to the data, Xingchuang Health Technology was established in October 2019, mainly engaged in health technology, medical technology, biotechnology, etc.
, and has cultivated and carried out "Xingfu Entrepreneurship Camp", "Xingfu Innovation Center", and "Xingfu Innovation and Entrepreneurship".
Contest" and many other brand projects focusing on innovation and incubation in the big health field, mainly for innovative entrepreneurs in the medical and health field, through the ecological community + innovation incubation model, to explore the frontier innovative fields of medical and health
.
As of the announcement date, Xingchuang Health Technology's registered capital is 5 million yuan
.
The business scope of Fosun Pharma includes biochemical products, reagents, and four biological technology services
.
The major shareholder of the company is Shanghai Fosun High-Tech (Group) Co.
, Ltd.
, which holds 36.
6% of the shares.
The latter is indirectly held by Fosun Holdings Co.
, Ltd.
72.
14%
.
The company has 41 foreign investment companies, of which 6 companies hold 100% of the shares
.
In the first three quarters of 2021, the company achieved total operating income of 27.
048 billion yuan, a year-on-year increase of 22.
38%; net profit attributable to shares was 3.
565 billion yuan, a year-on-year increase of 43.
80%; non-net profit was 2.
475 billion yuan, a year-on-year increase of 20.
19%
.
In the third quarter, Fosun Pharma achieved operating income of 10.
096 billion yuan, a year-on-year increase of 25.
03%, net profit attributable to equity of 1.
082 billion yuan, a year-on-year increase of 41.
62%, and realized non-net profit of 905 million yuan, a year-on-year increase of 19.
84%
.
On December 9, Fosun Pharma rose more than 5% in the afternoon.
As of the close of trading, it fell slightly by 0.
9%.
The stock is currently at 52.
27 yuan, with a turnover of 467 million
.
The related-party transactions were Windgothenburg and Fosun High-Tech.
The transferee shares accounted for 45% and 87%, respectively
.
Among them, Fosun Industrial, a subsidiary of Fosun Pharma, signed an "Equity Transfer Agreement" with Windgothenburg, a related party, and Fosun Industrial intends to invest US$28.
7 million in cash to acquire the 45% equity of FMH held by Windgothenburg
.
The main asset of FMH is its 100% equity interest in Breas
.
Fosun Pharma stated that this transaction does not constitute a major asset reorganization as required by the "Administrative Measures for the Major Asset Reorganization of Listed Companies"
.
Since Windgothenburg, the transferor of this transaction, is the holding subsidiary of Fosun International, the indirect controlling shareholder of the company, according to the Shanghai Stock Exchange’s Listing Rules and the “Guidelines for the Implementation of Related Party Transactions”, Windgothenburg constitutes a related party of the company and the transaction constitutes Related transactions of the company
.
It is understood that Breas and its holding subsidiaries are mainly engaged in professional ventilator design, research and development, manufacturing and sales.
Its medical and household ventilator products are sold in more than 40 countries around the world through its own channels and professional distribution networks.
Products include Vivo, Z series and other multifunctional ventilator and sleep ventilator products
.
According to the announcement, the consideration for the transaction is based on the value of all FMH shareholders’ equity as of September 30, as of September 30, which is based on the "Asset Appraisal Report" issued by Xiamen University Asset Appraisal Land and Real Estate Appraisal Co.
, Ltd.
It is determined after negotiation between the two parties in this transaction
.
After the completion of the transaction, Fosun Pharma will hold 100% of FMH
.
On the same day, Fosun Pharmaceutical Industries, a subsidiary of Fosun Pharmaceuticals, and Fosun High-Tech signed the "Equity Transfer Agreement.
" Equity
.
After the completion of the transaction, Fosun Pharmaceutical Industry will hold 87% of Xingchuang Health Technology, and Xingchuang Health Technology will be included in the scope of the consolidated financial statements of the Group
.
According to the data, Xingchuang Health Technology was established in October 2019, mainly engaged in health technology, medical technology, biotechnology, etc.
, and has cultivated and carried out "Xingfu Entrepreneurship Camp", "Xingfu Innovation Center", and "Xingfu Innovation and Entrepreneurship".
Contest" and many other brand projects focusing on innovation and incubation in the big health field, mainly for innovative entrepreneurs in the medical and health field, through the ecological community + innovation incubation model, to explore the frontier innovative fields of medical and health
.
As of the announcement date, Xingchuang Health Technology's registered capital is 5 million yuan
.
The business scope of Fosun Pharma includes biochemical products, reagents, and four biological technology services
.
The major shareholder of the company is Shanghai Fosun High-Tech (Group) Co.
, Ltd.
, which holds 36.
6% of the shares.
The latter is indirectly held by Fosun Holdings Co.
, Ltd.
72.
14%
.
The company has 41 foreign investment companies, of which 6 companies hold 100% of the shares
.
In the first three quarters of 2021, the company achieved total operating income of 27.
048 billion yuan, a year-on-year increase of 22.
38%; net profit attributable to shares was 3.
565 billion yuan, a year-on-year increase of 43.
80%; non-net profit was 2.
475 billion yuan, a year-on-year increase of 20.
19%
.
In the third quarter, Fosun Pharma achieved operating income of 10.
096 billion yuan, a year-on-year increase of 25.
03%, net profit attributable to equity of 1.
082 billion yuan, a year-on-year increase of 41.
62%, and realized non-net profit of 905 million yuan, a year-on-year increase of 19.
84%
.
On December 9, Fosun Pharma rose more than 5% in the afternoon.
As of the close of trading, it fell slightly by 0.
9%.
The stock is currently at 52.
27 yuan, with a turnover of 467 million
.
